Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice

Diabetes Research and Clinical Practice

Volumn 91, Issue 3, 2011, Pages 280-285

  Webb, D R ^a   Gray, L J ^a   Khunti, K ^a   Campbell, S ^b   Dallosso, H ^b   Davies, M J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cardiovascular disease; Diagnosis; Screening; Type 2 Diabetes

Indexed keywords

ANTITHROMBOCYTIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; HEALTH CARE PRACTICE; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MASS SCREENING; MIDDLE AGED; RISK FACTORS;

EID: 79952362672     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.021     Document Type: Article

References (22)

1. Saaddine J.B., Cadwell B., Gregg E.W., Engelgau M.M., Vinicor F., Imperatore G., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006, 144(7):465-474.
2. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48(5):937-942.
3. Booth G.L., Kapral M.K., Fung K., Tu J.V. Recent trends in cardiovascular complications among men and women with and without diabetes. Diab Care 2006, 29(1):32-37.
4. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.W. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
6. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: randomised placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
7. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
8. Gaede P., Lund-Andersen H., Parving H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
9. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H-, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348(5):383-393.
10. Lauritzen T., Griffin S., Borch-Johnsen K., Wareham N.J., Wolffenbuttel B.H.R., Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people type 2 diabetes detected by screening. Int J Obes 2000, 24(suppl. 3):S6-S11.
11. Sandbaek A., Griffin S.J., Rutten G., Davies M., Stolk R., Khunti K., et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk The ADDITION study. Diabetologia 2008, 51(7):1127-1134.
12. Department of Health. National Screening Committee; first report of the national screening committee. 1998.
13. Stevens R.J., Kothari V., Adler A.I., Stratton I.M., Holman R.R. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001, 101(6):671-679.
14. Gray LJ, Tringham JR, Davies MJ, Webb DR, Jarvis J, Skinner TC, Farooqi AM, Khunti K. Screening for Type 2 Diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study. Vascu Health Risk Manage 2010:6;837-42.
15. Webb D., Khunti K., Srinivasan B., Gray L., Taub N., Campbell S., et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010, 11(16).
16. Khunti K., Skinner T.C., Heller S., Carey M.E., Dallosso H.M., Davies M.J. Biomedical, lifestyle and psychosocial characteristics of people newly diagnosed with type 2 diabetes: Baseline data from the DESMOND randomized controlled trial. Diab Med 2008, 25(12):1454-1461.
17. Davies M.J., Heller S., Skinner T.C., Campbell M.J., Carey M.E., Cradock S., et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008, 336(7642):491-495.
18. Brindle P., May M., Gill P., Cappuccio F., D'Agostino R., Fischbacher C., et al. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006, 92(11):1595-1602.
19. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11(17).
20. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999, 281(21):2005-2012.
21. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, suppl 5:v1-52.
22. Gupta M., Singh N., Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation 2006, 113:e924-e929.